Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition
Authors
Keywords
-
Journal
Scientific Reports
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-01
DOI
10.1038/s41598-020-62813-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer
- (2019) Ryota Shibaki et al. Thoracic Cancer
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer
- (2019) Annett Schiwitza et al. Immunotherapy
- PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC
- (2019) Horiana B. Grosu et al. RESPIROLOGY
- Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response
- (2019) Alexander Haragan et al. LUNG CANCER
- OUP accepted manuscript
- (2018) EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non–Small Cell Lung Cancer Patients with Malignant Pleural Effusion
- (2018) Yen-Han Tseng et al. Journal of Thoracic Oncology
- Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis
- (2018) Ioannis Psallidas et al. LANCET ONCOLOGY
- Prognostic value of platelet count and lymphocyte to monocyte ratio combination in stage IV non-small cell lung cancer with malignant pleural effusion
- (2018) Jeong Uk Lim et al. PLoS One
- Prognostic and diagnostic impact of fibrinogen, neutrophil-tolymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome
- (2018) Stefan Janik et al. Oncotarget
- ERS/EACTS statement on the management of malignant pleural effusions
- (2018) Anna C. Bibby et al. EUROPEAN RESPIRATORY JOURNAL
- Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
- (2018) Yannis Metaxas et al. Journal of Thoracic Oncology
- PD-L1 expression in pleural effusions of pulmonary adenocarcinoma and survival prediction: a controlled study by pleural biopsy
- (2018) Jian Xu et al. Scientific Reports
- The next age of immunotherapy: optimisation, stratification and therapeutic synergies
- (2018) Niels Halama BRITISH JOURNAL OF CANCER
- Lung Macrophages: Multifunctional Regulator Cells for Metastatic Cells
- (2018) Naofumi Mukaida et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond
- (2017) Lee Pai‐Scherf et al. ONCOLOGIST
- Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis
- (2017) Stefan Janik et al. Oncotarget
- Prognostic value of PD –L1 expression in patients with primary solid tumors
- (2017) Xiao Xiang et al. Oncotarget
- PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
- (2017) Enrico Munari et al. Oncotarget
- Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
- (2017) Yuko Oya et al. Oncotarget
- Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma
- (2017) Thomas Klikovits et al. Scientific Reports
- Intrathoracic solitary fibrous tumor – an international multicenter study on clinical outcome and novel circulating biomarkers
- (2017) Bahil Ghanim et al. Scientific Reports
- Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study
- (2015) B Ghanim et al. BRITISH JOURNAL OF CANCER
- Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions
- (2015) Umut Sabri Kasapoglu et al. Clinical Respiratory Journal
- Platelets in cancer metastasis: To help the “villain” to do evil
- (2015) Nailin Li INTERNATIONAL JOURNAL OF CANCER
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elevated inflammatory parameters and inflammation scores are associated with poor prognosis in patients undergoing pulmonary metastasectomy for colorectal cancer
- (2015) Bahil Ghanim et al. Interactive Cardiovascular and Thoracic Surgery
- Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
- (2014) B Ghanim et al. BRITISH JOURNAL OF CANCER
- Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score
- (2014) Amelia O Clive et al. THORAX
- Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
- (2013) C. Zielinski et al. ANNALS OF ONCOLOGY
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Pretreatment Serum C-Reactive Protein Levels Predict Benefit From Multimodality Treatment Including Radical Surgery in Malignant Pleural Mesothelioma
- (2012) Bahil Ghanim et al. ANNALS OF SURGERY
- Clinical impact of ki-67 labeling index in non-small cell lung cancer
- (2012) Jan Nyrop Jakobsen et al. LUNG CANCER
- A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma
- (2011) Kyuichi Kadota et al. MODERN PATHOLOGY
- Ki67 in breast cancer: prognostic and predictive potential
- (2010) Rinat Yerushalmi et al. LANCET ONCOLOGY
- Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010
- (2010) M. E. Roberts et al. THORAX
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started